Data on the long-term management of patient receiving adalimumabfor hidradenitis suppurativa (HS) are scarce and mainly derived fromthe period 2 of the PIONEER studies. The aim of our retrospective study was to review epidemiologicaldata and analyze the therapeutic response, adverse effects, duration,and reasons of short suspension periods (SSP) during long-term anti-TNFαtherapy, in a real-life setting
Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience
Bettoli V.Primo
;Manfredini M.Secondo
;CALAMO, GIADA;Bencivelli D.;Corazza M.Ultimo
2018
Abstract
Data on the long-term management of patient receiving adalimumabfor hidradenitis suppurativa (HS) are scarce and mainly derived fromthe period 2 of the PIONEER studies. The aim of our retrospective study was to review epidemiologicaldata and analyze the therapeutic response, adverse effects, duration,and reasons of short suspension periods (SSP) during long-term anti-TNFαtherapy, in a real-life settingFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Bettoli_et_al-2018-Dermatologic_Therapy.pdf
solo gestori archivio
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.07 MB
Formato
Adobe PDF
|
1.07 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
